Whereas CAR T-cell therapy may be somewhat effective in eradicating EM ALL, blinatumomab has not demonstrated a similar ability to induce remission in EM ALL due to either resistance to the drug or the emergence of a CD19-negative leukemia cell line [56,62,63]. Here, CD19 is linked to acute lymphoblastic leukemia.